Haemophilia and cardiovascular disease in Japan: Low incidence rates from ADVANCE Japan baseline data.
anticoagulant therapy
atrial fibrillation
cardiovascular diseases
cardiovascular risk factors
haemophilia
ischemic events
Journal
Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
15
08
2023
received:
02
07
2023
accepted:
19
09
2023
medline:
14
11
2023
pubmed:
9
10
2023
entrez:
8
10
2023
Statut:
ppublish
Résumé
With the increasing life expectancy of people with haemophilia, the risk of cardiovascular disease (CVD) and thrombotic events has become a growing concern. Longitudinal studies on the incidence and risk factors of CVD in this population are limited, and optimal prevention and treatment strategies are yet to be established. This study aimed to present the baseline data of a prospective longitudinal study focusing on a subset of Japanese patients with haemophilia, specifically investigated the incidence, risk factors and treatment modalities for CVD and thrombotic diseases in people aged 40 years in Japan over 10 years through the ADVANCE Japan study. The ADVANCE Japan study is a prospective multicentre cohort study involving 600 adult individuals with haemophilia A/B aged 40 years in Japan. The primary endpoint was the incidence of CVD, with secondary endpoints encompassing anticoagulant use, mortality rates, and comparison with the general population. Baseline data from the 600 participants revealed that thrombotic events occurred in 13 individuals (2.2%), mostly in those with haemophilia A. Atrial fibrillation was observed in 11 participants (1.8%). Hypertension and dyslipidaemia were identified as the prevalent risk factors. Various prophylactic treatments were employed, and no severe bleeding events were observed during the study period. This study provides vital baseline data for a 10-year prospective investigation of CVD and thrombotic disease risk in people with haemophilia. These findings will contribute to refining prevention and treatment approaches and improving patients' quality of life.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1519-1528Subventions
Organisme : Bayer Yakuhin
ID : IIR-JP-2018-5970
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Badescu MC, Ciocoiu M, Rezus E, et al. Current therapeutic approach to acute myocardial infarction in patients with congenital hemophilia. Life. 2021;11:1072. doi:10.3390/life11101072
Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia. Haemophilia. 2020;26(6):1-158. doi:10.1111/hae.14046 Suppl
Shapiro AD, Hardesty BM, Peyvandi F, et al. Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: a scoping review. Res Pract Thromb Haemost. 2023;7:100007. doi:10.1016/j.rpth.2022.100007
Chen H, Yang S. Acute coronary syndrome management in hemophiliacs: how to maintain balance? A review. Medicine (Baltimore). 2023;102:e33298. doi:10.1097/MD.0000000000033298
Klamroth R, Ay C, De Moerloose P, et al. Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A-a modified Delphi consensus by the ADVANCE Working Group. Haemophilia. 2023;29:21-32. doi:10.1111/hae.14674
Nagao A, Suzuki N, Takedani H, et al. Ischaemic events are rare, and the prevalence of hypertension is not high in Japanese adults with haemophilia: first multicentre study in Asia. Haemophilia. 2019;25:e223-e230. doi:10.1111/hae.13749
Hori M, Connolly SJ, Zhu J, et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013;44:1891-1896. doi:10.1161/STROKEAHA.113.000990
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome. Accessed April 14, 2023. Available at: https://www.jstage.jst.go.jp/article/circj/83/5/83_CJ-19-0133/_article
Nakai M, Watanabe M, Kokubo Y, et al. Development of a cardiovascular disease risk prediction model using the suita study, a population-based prospective cohort study in Japan. J Atheroscler Thromb. 2020;27:1160-1175. doi:10.5551/jat.48843
Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. Accessed April 14, 2023. Available at: https://pubmed.ncbi.nlm.nih.gov/28536104/
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertension Research. Accessed April 14, 2023. Available at: https://www.nature.com/articles/s41440-019-0284-9
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. Accessed April 14, 2023. Available at: https://www.jstage.jst.go.jp/article/jat/25/9/25_GL2017/_article
Araki E, Goto A, Kondo T, et al. Japanese clinical practice guideline for diabetes 2019. Diabet Int. 2020;11. doi:10.1007/s13340-020-00439-5
Preface: evidence-based practice guideline for the treatment of chronic kidney disease. Clin Exp Nephrol. 2009;13:533-533. doi:10.1007/s10157-009-0235-x
Association between body mass index and cardiovascular disease mortality in east Asians and south Asians: pooled analysis of prospective data from the Asia Cohort Consortium. The BMJ. Accessed April 14, 2023. Available at: https://www.bmj.com/content/347/bmj.f5446
Faghmous I, Nissen F, Kuebler P, et al. Estimating the risk of thrombotic events in people with congenital hemophilia A using US claims data. J Comp Effect Res. 2021;10:1323-1336. doi:10.2217/cer-2021-0120
Guillet B, Cayla G, Lebreton A, et al. Long-term antithrombotic treatments prescribed for cardiovascular diseases in patients with hemophilia: results from the French registry. Thromb Haemost. 2021;121:287-296. doi:10.1055/s-0040-1718410
Badescu MC, Badulescu OV, Butnariu LI, et al. Cardiovascular risk factors in patients with congenital hemophilia: a focus on hypertension. Diagnostics (Basel). 2022;12:508. doi:10.3390/diagnostics12040508
NCD-RisC Collaboration Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957. doi:10.1016/S0140-6736(21)01330-1
Dorresteijn JAN, Visseren FLJ, Wassink AMJ, et al. SMART Study Group Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. Heart. 2013;99(12):866-872. doi:10.1136/heartjnl-2013-303640
Nationwide Survey on Coagulation Disorders of Japan. 2022. https://api-net.jfap.or.jp/library/project.html